JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258176

Human RPL22 knockout HEK-293T cell lysate

Be the first to review this product! 리뷰 제출

|

(0 출판물)

RPL22 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 1.
1 이미지
Sanger Sequencing - Human RPL22 knockout HEK-293T cell lysate (AB258176)
  • Sanger seq

Unknown

Sanger Sequencing - Human RPL22 knockout HEK-293T cell lysate (AB258176)

Homozygous : 2 bp deletion in exon 1

주요 정보

세포 유형

HEK-293T

Species or organism

Human

조직

Kidney

Knockout 검증

Sanger Sequencing

Mutation 정보

Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp deletion in exon 1.

제품 세부 정보

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

제품 구성

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258176-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human wild-type HEK293T cell lysate", "number":"AB258176-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human RPL22 knockout HEK293T cell lysate", "number":"AB258176-CMP01", "productcode":"" } ] } } }

특성 및 보관 정보

유전자명
RPL22
유전자 편집 종류
Knockout
유전자 편집 방식
CRISPR technology
Knockout 검증
Sanger Sequencing
Zygosity
Homozygous
배송 시 보관 조건
Ambient - Can Ship with Ice
적절한 단기 보관 조건
-20°C
적절한 장기 보관 조건
-20°C

추가 정보

This supplementary information is collated from multiple sources and compiled automatically.

RPL22 also known as Ribosomal Protein L22 is a component of the 60S subunit of ribosomes playing an important role in protein synthesis. It has an approximate molecular weight of 16 kDa. Expression of RPL22 occurs in various tissues but it shows high levels in the brain liver and spleen. The protein's structural role within the ribosome allows it to contribute to the assembly and stability necessary for ribosomal function.
Biological function summary

RPL22 contributes to ribosomal biogenesis by being part of a larger ribonucleoprotein complex. It participates in the assembly of the 60S subunit of ribosomes which is essential for translation. The proper function of RPL22 ensures accurate and efficient polypeptide elongation during protein synthesis. Being a part of the ribosomal machinery RPL22 impacts cell proliferation and growth as ribosomes are critical for producing proteins needed for cell development and function.

Pathways

RPL22 plays a role in the translation machinery impacting the protein synthesis pathway. It interacts with other ribosomal proteins such as RPL5 and RPL10 which together facilitate the translation of mRNA into protein. Additionally RPL22 has relevance in the mTOR signaling pathway an important regulator of cell growth and proliferation where it affects processes by influencing ribosomal output and protein translation directly.

RPL22 links to conditions such as cancer and Diamond-Blackfan anemia. Its aberrant expression or mutations can affect ribosome function contributing to tumorigenesis due to uncontrolled protein synthesis and cell proliferation. In particular studies show that leukemia and solid tumors may involve altered RPL22 activity. In Diamond-Blackfan anemia disrupted ribosomal biogenesis due to mutations in RPL22 associates with bone marrow failure. The protein's interactions with other ribosomal proteins like RPS19 help illustrate its potential involvement in these diseases.

품질 관리

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

제품 프로토콜

Product promise

저희는 고품질 시약으로 고객님의 연구를 서포트하고자 최선을 다하고 있으며, 모든 단계에서 함께 하겠습니다. 만약 제품이 기대한 성능을 보이지 않을 경우에도 Product Promise로 보호받으실 수 있습니다.
자세한 내용은 이용 약관을 확인해 주세요.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com